Peimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgad091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Yue Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, Jilin 130117, P. R. China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Dysbiosis, Dextran Sulfate, STAT Transcription Factors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jilin Science and Technology Development Plan Project, Young Scientist Program Training Program of Changchun University of Chinese Medicine, Jilin Traditional Chinese Medicine Science and Technology Project.
Abstract (Originalsprache)
Objectives
Inflammatory cytokine secretion and gut microbiota dysbiosis play crucial roles in ulcerative colitis. In this research, the protective effects of peimisine on colitis mice were investigated.
Methods
The protective effects were evaluated by the disease activity index, colonic length, hematoxylin–eosin, and AB/PAS Staining. The protective mechanisms were analyzed by ELISA, Western-blot, immunohistochemistry staining, immunofluorescence staining, and 16S rRNA gene analysis. Key findings The results showed that peimisine treatment could reduce the disease activity index, prevent colonic shortening, and alleviate colon tissue damage. Peimisine treatment also decreased the levels of MCP-1, IL-1β, IL-6, IFN-γ, TNF-α and affected macrophage polarization and Th17/Treg cell balance by downregulating the expression of jak1/2, p-jak1/2, stat1/3, and p-stat1/3. Moreover, peimisine treatment significantly increased the abundances of beneficial microbes (e.g. Ruminococcaceae UCG-014 and Lachnospiraceae_NK4A136_group) and decreased the abundances of harmful microbes (e.g. Bacteroides and Escherichia).
Conclusions
Peimisine can ameliorate colitis by inhibiting Jak–Stat signaling pathway, reversing gut microbiota alterations, suppressing macrophage M1 polarization, maintaining the Th17/Treg cell balance, and reducing sustained inflammatory cytokines-related inflammatory injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, Jilin 130117, P. R. China.
- Medical College, Yanbian University, Yanji 133002, P. R. China.
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, Jilin 130122, P. R. China.
ORCID-Profile: Yue Li
Förderung
- Jilin Science and Technology Development Plan Project
- Young Scientist Program Training Program of Changchun University of Chinese Medicine
- Jilin Traditional Chinese Medicine Science and Technology Project
Zitieren
APA
Li, Y., Yang, X., Han, J., Bai, B., Li, Y., Shang, C., Li, S., Xiu, Z., Liu, Z., Ge, C., Zhu, G., Jin, N., Fang, J., Li, Y., Li, X., & Zhu, Y. (2024). Peimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad091
Vancouver
Li Y, Yang X, Han J, Bai B, Li Y, Shang C, et al. Peimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgad091
BibTeX
@article{Li2024,
author = {Li, Yue and Yang, Xia and Han, Jicheng and Bai, Bing and Li, Yaru and Shang, Chao and Li, Shanzhi and Xiu, Zhiru and Liu, Zirui and Ge, Chenchen and Zhu, Guangze and Jin, Ningyi and Fang, Jinbo and Li, Yiquan and Li, Xiao and Zhu, Yilong},
title = {Peimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgad091}
}
EUVIMED